Home › Companies › NKTR

Nektar Therapeutics

Market cap $1.23B 34.2M shares (10-Q, Nov 6, 2026) × $35.91 close Nov 17, 2026

Most recent annual filing: 2026-03-13

Catalyst timeline

7 trackedQuarter catalyst calendar →
  1. amlitelimab Sanofi filing2H 2026amlitelimab Sanofi filing, 2H 2026, notable
  2. Rezpegaldesleukin trial start2H 2026Rezpegaldesleukin trial start, 2H 2026, routine
  3. undisclosed Treg indication trial start2H 2026undisclosed Treg indication trial start, 2H 2026, routine
  4. Rezpegaldesleukin AD readout1Q 2027Rezpegaldesleukin AD readout, 1Q 2027, major
  5. Rezpegaldesleukin T1D Ph2 interim2027Rezpegaldesleukin T1D Ph2 interim, 2027, notable
  6. AA registrational Phase 3 Ph3Early 2027AA registrational Phase 3 Ph3, Early 2027, routine
  7. Rezpegaldesleukin ZENITH Ph3 toplinemid-2028Rezpegaldesleukin ZENITH Ph3 topline, mid-2028, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (11 active programs)

Capital (as filed)

Cash
$34.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$580M Sep 30, 2026
Long-term investments
$339M Sep 30, 2026
Operating cash flow
−$71.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$953M cash, runway third quarter of 2028 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Nektar Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Nektar Therapeutics (NKTR) — Scientific Deep Dive for Rezpegaldesleukin and Pipeline Products First-in-class Treg biology and fortress balance sheet are real, but middling efficacy, a post-hoc-rescued AA primary, and a competitor a full cycle ahead in AD don't justify chasing a 570% move.
  2. Watch UPDATE: Nektar Therapeutics (NKTR) - The Phase 3 Clock Starts (and Amlitelimab's Head Start Widens) Phase 3 initiated on schedule but mid-2028 topline widens amlitelimab's commercial head start; stock at ~$69 prices M&A optionality after a 570%+21% run.
  3. Watch UPDATE: Nektar Therapeutics (NKTR) - The Runway Just Got a Deadline Q3-2028 runway guidance converts the cash cushion into a countdown that clears the mid-2028 ZENITH topline by only one quarter, and the AA registrational trial is now dated for early 2027.
  4. Watch UPDATE: Nektar Therapeutics (NKTR) - The Quiet Period Is the Catalyst The quiet-period 8-K signals the REZOLVE-AA 24-week off-treatment readout is weeks away, creating an asymmetric binary where a soft durability result does real damage to the AA thesis.
  5. Watch UPDATE: Nektar Therapeutics (NKTR) - The Docket Delivers $90M Jury awarded $90M non-dilutive cash against Lilly but it remains a contested receivable; stock near the February offering price with the AA durability binary still ahead.
  6. Watch UPDATE: Nektar Therapeutics (NKTR) - Eight Patients Carry the Durability Story AA off-treatment durability points the right way in 5/8 one-year responders but is built on n=8 with a weaker 36-week cohort; valuation near cash-plus-modest-pipeline level but Q1-2027 AD off-treatment data is the better entry trigger.
  7. Watch UPDATE: Nektar Therapeutics (NKTR) - The Premium Is Almost Gone Rezpeg's value above cash has compressed to ~$0.3B, meeting the price condition for revisiting, but the data condition (Q1 2027 AD off-treatment read) has not yet been met; a small starter position may be reasonable for patient investors.
  8. Watch UPDATE: Nektar Therapeutics (NKTR) - The Runway Is Back, and One Pivotal Changed Shape Runway into Q3 2028 reaffirmed and burn partly explained by prepayments, but ZENITH AD-2 redesign as a TCS-combination trial removes naïve monotherapy replication; a small starter position remains reasonable ahead of Q1 2027 durability data.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (33)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 21, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)